-- Barclays, GlaxoSmithKline, RBS, Sage: U.K., Irish Equity Preview
-- B y   B e n   M a r t i n   a n d   A l e x i s   X y d i a s
-- 2010-10-08T06:46:57Z
-- http://www.bloomberg.com/news/2010-10-07/barclays-glaxosmithkline-rbs-u-k-irish-equity-preview.html
The following is a list of companies
whose shares may have unusual price changes in U.K. and Irish
markets. Stock symbols are in parentheses and prices are from
the last market close.  The benchmark  FTSE 100 Index  lost 19.26, or 0.3 percent, to
5,662.13. The  FTSE All-Share Index  also retreated 0.3 percent
and Ireland’s ISEQ Index dropped 0.7 percent.  Barclays Plc  (BARC LN): Nomura Holdings Inc. put 220
million shares in Britain’s third-biggest bank up for sale
overnight in connection with hedging activities on behalf of a
holding controlled by Abu Dhabi’s ruling family. The shares were
offered at 290 pence to 295 pence apiece, according to terms of
the offer obtained by Bloomberg News. The transaction allows Abu
Dhabi, which remains a shareholder, to hedge its entire stake.
The shares fell 0.9 percent to 304.1 pence.       Fresnillo Plc  (FRE LN): The mining company was cut to
“underperform” from “neutral” at BofA Merrill Lynch Global
Research. The shares dropped 2 percent to 1,289 pence.  GlaxoSmithKline Plc  (GSK LN): The U.K.’s biggest drugmaker
appointed  Christophe Weber  as president designate of the
company’s vaccine unit to replace  Jean Stephenne , the current
head of the division, who is retiring. The stock advanced 1.9
percent to 1,296.5 pence.  Royal Bank of Scotland Group Plc  (RBS LN): JPMorgan Chase &
Co., the second-largest U.S. bank by assets, agreed to buy the
North American natural-gas and power-trading book from a joint
venture between RBS and Sempra Energy for about $220 million.
The shares dropped 3.4 percent to 47.8 pence.  Sage Group Plc  (SGE LN): The U.K. software maker was cut to
“sell” from “neutral” by UBS AG. The shares rose 0.4 percent
to 282.5 pence.  To contact the reporters on this story:
 Ben Martin  in London at   bmartin38@bloomberg.net ;
Alexis Xydias in London at 
 axydias@bloomberg.net .  To contact the editor responsible for this story:
David Merritt at 
 merritt1@bloomberg.net . 